NCT03703466 - A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

July 29, 2019

Study Completion Date

March 9, 2023

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Abemaciclib

Administered orally.

Trial Locations (15)

2010

St Vincent's Hospital, Sydney

2291

Mater Private Hospital, North Sydney

3000

Peter MacCallum Cancer Centre, Melbourne

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

5037

Ashford Cancer Centre Research, Kurralta Park

22030

Trakya University Faculty of Medicine, Edirne

28034

Hospital Ruber Internacional, Madrid

28040

Hospital Clinico San Carlos, Madrid

35575

Medical Park Izmir Hospital, Izmir

44280

Inonu University Medical Faculty, Malatya

115478

Russian Oncological Research Center, Moscow

400138

Volgograd regional clinical oncology dispensary, Volgograd

08023

Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

07058

Akdeniz University Medical Faculty, Antalya

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY